Drug Profile
Belumosudil - Kadmon Pharmaceuticals
Alternative Names: Belumosudil mesylate - Kadmon Pharmaceuticals; BN-101; KD-025; KD025 mesylate; ME-3208; REZUROCK; Rholistiq; SAR445761; SLX-2119Latest Information Update: 02 Apr 2024
Price :
$50
*
At a glance
- Originator Surface Logix
- Developer BK Pharmaceuticals; Kadmon Pharmaceuticals; Meiji Seika Pharma; Sanofi
- Class Acetamides; Amines; Anti-inflammatories; Antifibrotics; Antipsoriatics; Antirheumatics; Hepatoprotectants; Indazoles; Phenyl ethers; Quinazolines; Skin disorder therapies; Small molecules
- Mechanism of Action Rho-associated kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Graft-versus-host disease
- Phase III Lung transplant rejection
- Phase II Idiopathic pulmonary fibrosis; Systemic scleroderma
- Phase I Autoimmune disorders
- Preclinical Multiple myeloma
- Discontinued Non-alcoholic steatohepatitis; Plaque psoriasis; Rheumatoid arthritis; Systemic lupus erythematosus
Most Recent Events
- 26 Mar 2024 Registered for Graft-versus-host disease in Japan (PO)
- 11 Dec 2023 Kadmon Corporation terminates the phase II The ROCKstar Study in Graft-versus-host disease (In adolescents, In adults, Treatment-experienced) in USA (PO) due to the sponsor decision to prematurely terminate the study due to the challenges encountered in recruiting adolescent participants (NCT03640481)
- 09 Dec 2023 Preclinical trials in Multiple myeloma in France (unspecified route) prior to December 2023